Not Signed In -
Furosemide Oral Solution |
Lasix Oral Solution |
Clinical Trial: Extracellular Fluid in Resistant Hypertension
This study is currently recruiting patients.
Verified by St George''''s, University of London August 2005
|
Purpose
The optimal treatment of drug resistant (defined as BP> 140/85 despite three anti-hypertensive drugs including a diuretic) is not well defined. This study aims to test the hypothesis that resistant hypertension is caused by excessive expansion of extracellular fluid volume. A secondary objective is to study which of three different antihypertensive drugs would be most useful in drug resistant hypertension.
| Condition | Intervention |
|---|---|
| Hypertension | Drug: Cardura XL 4 mg bd Drug: Amiloride 5 mg bd Drug: Furosemide 40 mg bd |
MedlinePlus related topics: High Blood Pressure
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Official Title: A Study to Investigate the Contribution of Extracellular Fluid Volume Expansion to Drug Resistant Hypertension
Further Study Details:
Primary Outcomes: Change in ECV; change in BP
Expected Total Enrollment: 32
Expected Total Enrollment: 32
Study start: July 2003; Expected completion: October 2006
Following recruitment subjects will have ECV measured by 51Cr-EDTA determination of GFR, with Brochner-Mortensen correction applied. Subjects then receive the following drugs, in a randomised fashion, for a period of four weeks each, with BP & ECV measurement at end of each period: doxazosin GITS (Cardura XL) 4 mg b.d.; frusemide 40 mg b.d.; amiloride 5 mg b.d.; placebo.
Eligibility
Ages Eligible for Study: 18 Years - 80 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- BP >140/85
- 3 antihypertensive drugs (ACE/ARB + calcium channel blocker + thiazide diuretic)
Exclusion Criteria:
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00141596
Timothy WR Doulton, BSc MRCP +44 208 725 3176 Ext. - tdoulton@sgul.ac.uk
United Kingdom
Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL, London, SW17 0RE, United Kingdom; Recruiting
Timothy WR Doulton, BSc MRCP +44 208 725 3176 Ext. - tdoulton@sgul.ac.uk
Timothy WR Doulton, BSc MRCP, Principal Investigator
Timothy WR Doulton, BSc MRCP, Principal Investigator
Study chairs or principal investigators
Timothy WR Doulton, BSc MRCP, Principal Investigator, SGUL
More Information
Study ID Numbers: LREC 03.0001
Last Updated: August 31, 2005
Record first received: August 31, 2005
ClinicalTrials.gov Identifier: NCT00141596
Health Authority: United Kingdom: Research Ethics Committee
ClinicalTrials.gov processed this record on 2005-09-06
Last Updated: August 31, 2005
Record first received: August 31, 2005
ClinicalTrials.gov Identifier: NCT00141596
Health Authority: United Kingdom: Research Ethics Committee
ClinicalTrials.gov processed this record on 2005-09-06
Resources
- Furosemide Oral Solution (Drug Digest)
- Lasix Oral Solution (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
